Show simple item record

dc.contributor.authorSharma, RAen_US
dc.contributor.authorPlummer, Ren_US
dc.contributor.authorStock, JKen_US
dc.contributor.authorGreenhalgh, TAen_US
dc.contributor.authorAtaman, Oen_US
dc.contributor.authorKelly, Sen_US
dc.contributor.authorClay, Ren_US
dc.contributor.authorAdams, RAen_US
dc.contributor.authorBaird, RDen_US
dc.contributor.authorBillingham, Len_US
dc.contributor.authorBrown, SRen_US
dc.contributor.authorBuckland, Sen_US
dc.contributor.authorBulbeck, Hen_US
dc.contributor.authorChalmers, AJen_US
dc.contributor.authorClack, Gen_US
dc.contributor.authorCranston, ANen_US
dc.contributor.authorDamstrup, Len_US
dc.contributor.authorFerraldeschi, Ren_US
dc.contributor.authorForster, MDen_US
dc.contributor.authorGolec, Jen_US
dc.contributor.authorHagan, RMen_US
dc.contributor.authorHall, Een_US
dc.contributor.authorHanauske, A-Ren_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorHaswell, Ten_US
dc.contributor.authorHawkins, MAen_US
dc.contributor.authorIllidge, Ten_US
dc.contributor.authorJones, Hen_US
dc.contributor.authorKennedy, ASen_US
dc.contributor.authorMcDonald, Fen_US
dc.contributor.authorMelcher, Ten_US
dc.contributor.authorO'Connor, JPBen_US
dc.contributor.authorPollard, JRen_US
dc.contributor.authorSaunders, MPen_US
dc.contributor.authorSebag-Montefiore, Den_US
dc.contributor.authorSmitt, Men_US
dc.contributor.authorStaffurth, Jen_US
dc.contributor.authorStratford, IJen_US
dc.contributor.authorWedge, SRen_US
dc.contributor.authorNCRI CTRad Academia-Pharma Joint Working Groupen_US
dc.date.accessioned2016-08-26T15:13:03Z
dc.date.issued2016-10en_US
dc.identifier.citationNature reviews. Clinical oncology, 2016, 13 (10), pp. 627 - 642en_US
dc.identifier.issn1759-4774en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/74
dc.identifier.eissn1759-4782en_US
dc.identifier.doi10.1038/nrclinonc.2016.79en_US
dc.description.abstractIn countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.en_US
dc.formatPrint-Electronicen_US
dc.format.extent627 - 642en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectNCRI CTRad Academia-Pharma Joint Working Groupen_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectCombined Modality Therapyen_US
dc.subjectDrug Approvalen_US
dc.subjectRadiation Dosageen_US
dc.subjectCell Hypoxiaen_US
dc.subjectRadiation Toleranceen_US
dc.subjectPatient Participationen_US
dc.subjectQuality of Health Careen_US
dc.subjectQuality Assurance, Health Careen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectPatient Education as Topicen_US
dc.titleClinical development of new drug-radiotherapy combinations.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-05-15en_US
rioxxterms.versionofrecord10.1038/nrclinonc.2016.79en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2016-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNature reviews. Clinical oncologyen_US
pubs.issue10en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHall, Emmaen_US
dc.contributor.icrauthorHarrington, Kevinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record